title: RimabotulinumtoxinB versus OnabotulinumtoxinA in the treatment of masseter hypertrophy: a 24-week double-blind randomized split-face study.
abstract: BACKGROUND
  Masseter hypertrophy can be ameliorated by botulinum toxin.
  
  
  OBJECTIVE
  To compare the efficacy and safety of RimabotulinumtoxinB (BTX-B) and OnabotulinumtoxinA (BTX-A) in the treatment of masseter hypertrophy.
  
  
  METHODS
  Sixteen women with bilateral masseter hypertrophy received single injections of BTX-A or BTX-B at a dose ratio of 1:50 or 1:70 in a 24-week double-blind randomized split-face study.
  
  
  RESULTS
  Both BTX-A and BTX-B produced significant improvements in masseter hypertrophy. The maximum volume reduction, as determined by computed tomography scanning, at week 12 was comparable between BTX-A and BTX-B at a dose ratio of 1:70 (15.6 and 14.2%, respectively). At week 24, only masseters treated with BTX-A maintained a significant volume reduction. Investigator ratings and patient satisfaction scores paralleled objective computed tomography measurements.
  
  
  CONCLUSIONS
  Both BTX-A and BTX-B are effective in the treatment of masseter hypertrophy. BTX-B, at a dose ratio of 1:70, has a comparable efficacy but a shorter duration of action than BTX-A.
authors.affiliation: Department of Dermatology, Seoul National University College of Medicine, Institute of Human-Environment Interface Biology, Seoul National University, Seoul, Korea.
authors.forename: Dong Hun
authors.initials: DH
authors.lastname: Lee
authors.forename: Seon-Pil
authors.initials: SP
authors.lastname: Jin
authors.forename: Soyun
authors.initials: S
authors.lastname: Cho
authors.forename: Ashley
authors.initials: A
authors.lastname: Feneran
authors.forename: Choon Shik
authors.initials: CS
authors.lastname: Youn
authors.forename: Chong Hyun
authors.initials: CH
authors.lastname: Won
authors.forename: Gyeong-Hun
authors.initials: GH
authors.lastname: Park
authors.forename: Byung Wook
authors.initials: BW
authors.lastname: Kim
authors.forename: Jeesoo
authors.initials: J
authors.lastname: An
authors.forename: Sung Eun
authors.initials: SE
authors.lastname: Chang
authors.forename: Mi Woo
authors.initials: MW
authors.lastname: Lee
mesh_terms: D000328:Adult; D001905:Botulinum Toxins / Q000009:adverse effects / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use*; D003357:Cosmetic Techniques; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006984:Hypertrophy / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008406:Masseter Muscle / Q000002:abnormalities* / Q000000981:diagnostic imaging; D009465:Neuromuscular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017060:Patient Satisfaction; D014057:Tomography, X-Ray Computed; D055815:Young Adult
chemical_list: D009465:Neuromuscular Agents; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A